Apellis Pharmaceuticals, Inc.
APLS
$21.99
$0.743.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 156.92% | 7.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 156.92% | 7.01% | |||
| Cost of Revenue | 14.98% | -33.23% | |||
| Gross Profit | 273.89% | 112.65% | |||
| SG&A Expenses | 8.80% | 1.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.15% | -15.33% | |||
| Operating Income | 770.50% | 60.05% | |||
| Income Before Tax | 618.93% | 54.63% | |||
| Income Tax Expenses | 29.18% | 36.66% | |||
| Earnings from Continuing Operations | 611.77% | 54.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 611.77% | 54.30% | |||
| EBIT | 770.50% | 60.05% | |||
| EBITDA | 780.64% | 60.38% | |||
| EPS Basic | 610.10% | 54.50% | |||
| Normalized Basic EPS | 617.37% | 54.85% | |||
| EPS Diluted | 599.25% | 54.50% | |||
| Normalized Diluted EPS | 602.85% | 54.85% | |||
| Average Basic Shares Outstanding | 0.32% | 0.46% | |||
| Average Diluted Shares Outstanding | 3.21% | 0.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||